TCTR20170301001进行中（未招募）3 期
A Prospective, Randomized, Double-blind, Placebo-controlled Phase 3 Study of VGX-3100 delivered Intramuscularly followed by Electroporation with CELLECTRA 5PSP for the Treatment of HPV-16 and/or HPV-18 related HSIL of the cervix.
Inovio Pharmaceuticals, Inc.0 个研究点目标入组 201 人开始时间: 2017年3月1日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 201
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 0 N/A (No limit)（—）
- 性别
- Female
入选标准
- •â€¢Women aged 18 years and above
- •â€¢Confirmed cervical infection with HPV types 16 and/or 18 at screening
- •â€¢Cervical tissue specimen/slides provided to Study Pathology Adjudication Committee for diagnosis scheduled to be collected within 10 weeks prior to anticipated date of first dose of study drug
- •â€¢Confirmed histologic evidence of cervical HSIL at screening
- •â€¢Must be judged by Investigator to be an appropriate candidate for the protocol-specified procedure required at Week 36
- •â€¢With respect to their reproductive capacity must be post-menopausal or surgically sterile or willing to use a contraceptive method with failure rate of less than 1% per year when used consistently and correctly from screening until Week 36
- •â€¢Normal screening electrocardiogram (ECG)
排除标准
- •â€¢Microscopic or gross evidence of adenocarcinoma-in-situ (AIS), high grade vulvar, vaginal, or anal intraepithelial neoplasia or invasive cancer in any histopathologic specimen at screening
- •â€¢Cervical lesion(s) that cannot be fully visualized on colposcopy
- •â€¢History of endocervical curettage (ECC) which showed cervical HSIL indeterminate, or insufficient for diagnosis
- •â€¢Treatment for cervical HSIL within 4 weeks prior to screening
- •â€¢Pregnant, breastfeeding or considering becoming pregnant during the study
- •â€¢History of previous therapeutic HPV vaccination
- •â€¢Immunosuppression as a result of underlying illness or treatment
- •â€¢Receipt of any non-study, non-live vaccine within 2 weeks of Day 0
- •â€¢Receipt of any non-study, live vaccine within 4 weeks of Day 0
- •â€¢Current or history of clinically significant, medically unstable disease or condition which, in the judgment of the investigator, would jeopardize the safety of the participant, interfere with study assessments or endpoint evaluation, or otherwise impact the validity of the study results
- •â€¢Presence of acute or chronic bleeding or clotting disorder that would contraindicate IM injections, or use of blood thinners within 2 weeks of Day 0
- •â€¢Participation in an interventional study with an investigational compound or device within 30 days of signing informed consent
- •â€¢Less than two acceptable sites available for IM injection
研究者
相似试验
已完成
4 期
A clinical trial to study the effect of Desmopressin Intranasal Solution BP (Mfd. by Biodeal Laboratories Pvt. Ltd.) Vs. Desmopressin Intranasal Solution BP (Mfd. by Ferring Pharmaceuticals Ltd.) in patients diagnosed with Central Cranial Diabetes Insipidus.CTRI/2010/091/001415Biodeal Laboratories Pvt. Ltd 508, G.I.D.C Estate, Wadhwan city, Dist Surendranagar,Gujarat - 36303562
进行中（未招募）
1 期
A prospective, randomized, cross-over,double blind study to evaluate if paricalcitol antiproteinuric effect in type 2 patients and stable RAS inhibitory therapy depens on dietary sodium intakeType 2 diabetesMedDRA version: 14.1 Level: LLT Classification code 10045242 Term: Type II diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2011-001713-14-ITIST. DI RICERCHE FARMACOLOG. M. NEGRI115
尚未招募
2 期
Heparin sodium topical solution 1000 IU/ ml in the treatment of thrombophlebitis associated with varicose veiCTRI/2018/05/013701Troikaa Pharmaceuticals Limited
进行中（未招募）
1 期
A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-inferiority Study Comparing the Efficacy and Safety of Once Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation (39039039AFL3001)EUCTR2006-004595-13-GBBayer HealthCare AG14,000
进行中（未招募）
1 期
A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-inferiority Study Comparing the Efficacy and Safety of Once Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation (39039039AFL3001)EUCTR2006-004595-13-BGBayer HealthCare AG14,000